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Abstract
Background: The aetiology of testicular cancer remains elusive. In this manuscript, we review the evidence regarding
the association between cannabis use and testicular cancer development.
Methods: In this systematic review and meta-analysis, we reviewed literature published between 1st January 1980 and
13th May 2015 and found three case–control studies that investigated the association between cannabis use and
development of testicular germ cell tumours (TGCTs).
Results/Conclusions: Using meta-analysis techniques, we observed that a) current, b) chronic, and c) frequent
cannabis use is associated with the development of TGCT, when compared to never-use of the drug. The strongest
association was found for non-seminoma development – for example, those using cannabis on at least a weekly basis
had two and a half times greater odds of developing a non-seminoma TGCT compared those who never used
cannabis (OR: 2.59, 95 % CI 1.60–4.19). We found inconclusive evidence regarding the relationship between cannabis
use and the development of seminoma tumours. It must be noted that these observations were derived from three
studies all conducted in the United States; and the majority of data collection occurred during the 1990’s.
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Background
The cannabis plant has been ingested or inhaled by
humans for more than 4000 years [1]. In the 2014
United Nations World Drug Report, it was estimated
that some 178 million 15–64 year-olds worldwide use
cannabis at least once per year – making it the most
consumed illicit drug by a factor of five [2]. Substantial
variability in the consumption of cannabis has been ob-
served between (and within) populations – with preva-
lence considerably higher in the Americas, Europe and
Oceania compared to Asia and Africa [2].
Testicular cancer is the most common cancer among
young men, with peak incidence occurring between 15
and 40 years of age [3] and the highest rates of disease
found among men who can trace their ancestry to
Northern Europe [4]. Rates of testicular cancer appear
to be increasing rapidly over time [5] – and yet the
primary exposures involved in its aetiology remain
poorly understood [6].
In recent years, at least three case–control studies re-
ported associations between cannabis exposure and tes-
ticular germ cell tumour (TGCT) development [7–9]. A
recent meta-analysis of these studies showed that those
who used cannabis for longer than 10 years were 50 %
more likely to develop testicular cancer than those who
never used cannabis (summary odds ratio [OR]: 1.50,
95 % CI 1.08–2.09) [10]. However, this review was lim-
ited in two ways: firstly, it did not assess the quality of
the case–control studies – an important step toward un-
derstanding potential sources of bias introduced by the
authors; and secondly, it did not differentiate between
seminoma and non-seminoma tumour types [10] – which
is also important, since a) non-seminoma tumours are
typically diagnosed seven [11] to ten [12] years earlier than
seminoma tumours, and may differ in terms of risk fac-
tors; and b) each of the studies showed a stronger associ-
ation for non-seminoma tumours than for seminoma
tumours. This review aims to address these issues.
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Methods
In order to summarise the current evidence regarding the
strength of association between cannabis exposure and
testicular cancer, a systematic review and meta-analysis of
the literature were undertaken. The review was performed
in accordance with the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) guidelines [13].
Search strategy
All articles published between 1st Jan 1980 and 13th May
2015 were eligible for inclusion. No limits were set in
terms of language used or study design. A search of elec-
tronic databases was conducted on 13th March 2015
using the following databases: Cinahl, Cochrane Library,
Embase, Medline, ProQuest Central, ProQuest Disserta-
tions and Theses, Scopus and Web of Science. Using a
Boolean approach, we searched the electronic databases
for any possible combination of the keywords listed in
Table 1.
The reference lists of those studies which were consid-
ered eligible for inclusion (see below) were scanned for
additional relevant studies. Two international experts in
the field of testicular cancer and/or cancer epidemiology
were contacted via email, and given a list of those stud-
ies which met our inclusion criteria. They were asked to
identify any studies that had been missed by our search.
Study inclusion
References were collected and logged in EndNote vX7.1
(Thomson Reuters, New York, U.S.A.). Duplicate re-
cords were removed prior to further analysis. Abstracts
were screened by one reviewer (JG) to remove irrelevant
studies, with a 10 % random sample of these verified by
a second reviewer (VS). Any disagreements about inclu-
sion were resolved by referral to a third reviewer (DS).
The full text of all remaining papers was obtained and
assessed by two reviewers (JG and VS) to identify those
which met our inclusion criteria.
Studies included in the final analysis were those that
reported associations between cannabis and testicular
cancer. Studies were only included if data were provided
from which summary associations (odds ratio or relative
risks) and their 95 % confidence intervals could be cal-
culated, or if these summary associations were provided
by the authors themselves. All manuscripts that were con-
sidered relevant during the abstract screening process but
ineligible for inclusion in our final analysis are listed in the
supplementary material, along with justification for why
they were ultimately excluded (Additional file 1).
Data extraction
For each included study, one reviewer (JG) extracted
meta-data, which was then verified by a second reviewer
(VS). Meta-data included: study design, year of publica-
tion, location of study, sample size (cases/controls)
sources of data, exclusion criteria, adjustment for con-
founding, methods of cannabis exposure measurement,
and estimate of the association between outcome and
exposure (Table 2).
Assessment of study quality
The assessment of study quality and potential for bias is
an essential feature of any systematic review. However,
there remains no gold standard measure of study quality
for observational research. In the absence of such a gold
standard, it has been recommended that any tools used
to measure study quality should be as specific as possible
to the given topic, and involve a simple checklist as op-
posed to a scale or score [14]. Given these factors, we
assessed study quality and potential for bias using the
criteria outlined in the Newcastle-Ottawa Quality As-
sessment Scale [15, 16], but did not determine a quality
score [17]. Two reviewers (JG and JS) independently
assessed study quality against these criteria, with dis-
agreements resolved by referral to a third reviewer (DS).
Statistical analysis
Adjusted odds ratios were extracted from each included
study (along with their 95 % confidence intervals). We
tested for evidence of heterogeneity between studies
using both the X2 (p <0.1 indicating high inter-study het-
erogeneity) [18, 19] and I2 (0 % indicating no inter-study
heterogeneity) [15, 19] tests. Using a random-effects
model, we applied inverse-variance weighted methods
for combining results across included studies to arrive at
a final summary odds ratio (and associated 95 % confi-
dence intervals) for the association between various
levels of cannabis exposure and testicular cancer out-
come (total and stratified by seminoma/non-seminoma
tumours) [20]. This analysis was completed in Stata
v11.2 using the metan function [21].
Results
Our search strategy resulted in the initial identification of
149 records. Forty-nine duplicate records were removed,
leaving 100 unique studies. A further 84 records were
Table 1 List of exposure- and outcome-related keywords
Exposure-related keywords Outcome-related keywords
Cannabia Cancer of the testia
Marijuana Seminomaa
Marihuana [29, 30] Testia cancer
THC [31] Testia carcinoma
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removed as a result of abstract screening, which left a total
16 records for full-text screening to determine eligibility
for analysis. No further records were added by scanning
the reference list of the 16 records (Fig. 1).
Following full-text screening, 10 records were removed
due to either lack of primary data or lack of relevance to
the topic. A further 3 records were removed due to their
primary data being formally published elsewhere – for
example, primary data from a PhD thesis that was subse-
quently published in a peer-reviewed journal (Additional
file 1). Following systematic review and exclusions,
a total of 3 relevant case–control studies were found
Fig. 1 Flow chart of systematic review investigating association between cannabis exposure and testicular cancer development
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[7–9]. No cohort studies were found. Our invited
experts both advised that they were unaware of any
additional published studies of relevance to this review.
Meta-data for included studies
Meta-data for each of the included studies are presented
in Table 2. Each of the included studies were conducted
in the United States, with the earliest recruitment occur-
ring in 1986 [8] and the most recent occurring in 2006
[9]. A total of 719 cases with testicular germ cell tu-
mours (TGCT) participated across the three studies,
along with a total of 1419 controls. In all studies, cases
were identified from local cancer registries and con-
firmed via review of pathology reports. In terms of histo-
logical type, two of the three studies separated the
cohort into seminoma and non-seminoma sub-groups
[8, 9], while the other study additionally separated non-
seminoma tumours into non-seminoma and mixed-type
sub-groups [7].
Controls were either randomly derived from the com-
munity [8, 9] or the friend of cases [7]. All three studies
matched on age, while two of the three studies matched
on region of residence [8, 9]. Two of the three studies
also matched cases and controls on race and/or ethnicity
[7, 8]. Two of the three studies [7, 9] frequency-matched
controls to cases, while one study individually-matched
controls to cases [8].
Cannabis exposure was measured using self-report, ei-
ther via face-to-face interview [8, 9] or self-completed
paper-based questionnaire [7]. Each of the included stud-
ies asked the participant to report ever-use of cannabis,
the duration of use and the frequency of use – with one
study also asking about age at first use [9].
With respect to adjustment for confounding – in
addition to the covariates used to match controls to
cases – all three studies adjusted for history of crypt-
orchidism, two of the studies additionally adjusted for
use of alcohol and tobacco. [7, 9] One study also ad-
justed for other drug use (including amyl nitrate and co-
caine), religiosity and education level [8].
Assessment of study quality
The assessment of study quality against the Newcastle-
Ottawa criteria is presented in Table 3. Case definition
was adequate for all included studies, with registry re-
cords independently validated via review of pathology re-
cords. In terms of case representativeness, two of the
included studies restricted their participants to those aged
between 18 and 44–50 – with such practice being com-
mon in the testicular cancer context since a) the vast ma-
jority of cases occur within this age band, and b) it is
thought that the aetiology of tumours that occur in youn-
ger or older populations differs to those that occur among
this 18–50 year age group. One study (Lacson et al. [8])
further restricted their study groups to those aged 18–35.
Each of the included studies derived their controls
from the community, although one study used the friend
of cases as controls [7], which may have reduced the
representativeness of the control sample in that study.
All controls had no history of testicular cancer. Each of
the studies measured cannabis exposure in the same way
(via self-report), although one asked about hashish expos-
ure specifically as well as cannabis. For those studies in
which person-to-person interview was conducted [8, 9],
there is no record that interviewers were blinded as to the
case/control status of the participant.
In order to maximise the comparability of cases and
controls, each of the studies matched controls to cases –
or adjusted in their regression modelling – for what
could be considered the two strongest confounding vari-
ables (age and history of cryptorchidism).
Two of the included studies reported highly-differential
response rates for cases and controls. One of these studies
reported the highest response rate among cases (response
rate: cases 67.5 %, controls 43.3 %) [9], while the other re-
ported the highest response rate among controls (cases
38.2 %, controls 73.3 %) – the latter study deriving their
controls from friends of cases [7]. The remaining study re-
ported high and near-identical response rates between
cases and controls (cases 81.0 %, controls 78.7 %) [8].
Meta-analysis results
In terms of overall association, our meta-analysis was in-
conclusive regarding the association between ever-use of
cannabis and development of TGCT (pooled odds ratio
[OR], ever-use compared with never use): 1.19, 95 % CI
0.72–1.95), and for the association of former use with
TGCT (OR: 1.54, 95 % CI 0.84–2.85). We observed that
current use of cannabis increased the odds of TGCT
development by 62 % (OR: 1.62, 95 % CI 1.13–2.31).
Frequency of cannabis was associated with TGCT de-
velopment, with weekly (or greater) use appearing to
nearly doubling the odds of TGCT development (OR:
1.92, 95 % CI 1.35–2.72). There was also evidence of an
association between the duration of cannabis use (> =
10 years vs. never use) and TGCT development (OR:
1.50, 95 % CI 1.08–2.09).
There was insufficient evidence to conclude that can-
nabis use was associated with seminoma development
(Fig. 2). However, there was evidence of an association be-
tween cannabis use and non-seminoma development –
with current use more than doubling the odds of tumour
development (OR: 2.09, 95 % CI 1.29–3.37). Frequency of
use was also strongly associated with non-seminoma de-
velopment, with those using cannabis on at least a weekly
basis having two and a half times greater odds of tumour
development compared those who never used cannabis
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Table 3 Assessment of the quality of studies included in current meta-analysis against the Newcastle-Ottawa criteria [16]













for cases and controls























Yes (7) Rate different
(Response rate:
cases 67.5 %/
controls 43.3 %) (8)
Low response rate among
































Low response rate among cases.
Controls recruited as friends of























Yes (23) Same rate for both
groups (Response
rate: cases 81.0 %/
controls 78.7 %)
(24)
Minimised to those aged 18–35
(limits representativeness)
Explanation of categorisations is presented in Additional file 2 alongside its corresponding number


















(OR: 2.59, 95 % CI 1.60–4.19). Finally, those who had used
cannabis for at least 10 years had nearly two and half
times the odds of non-seminoma development compared
to never-users (OR: 2.40, 95 % CI 1.52–3.80).
In terms of heterogeneity, a high level of agreement
between studies was found – with I2 values of 0 % ob-
served for most exposure variables (Fig. 2b-d). A notable
exception was the ever-use variable (Fig. 2a), for which
I2 values ranged between 59 % (non-seminoma tumour
type) and 71 % (combined tumour types).
Discussion
The results of this review show that current use of can-
nabis (pooled summary OR: 1.62, 95 % CI 1.13–2.31),
using cannabis on at least a weekly basis (OR: 1.92, 95 %
CI 1.35–2.72) and long duration (>10 years) of cannabis
use (OR: 1.50, 95 % CI 1.08–2.09) are all associated with
an increased risk of development of TGCT overall, and
even more strongly with non-seminoma tumours specif-
ically. There was insufficient evidence to conclude that
there is a relationship between seminoma tumours and
cannabis use.
Thus, our meta-analyses suggest that a strong associ-
ation exists between TGCT development and current,
chronic and/or frequent cannabis use – particularly
non-seminoma development –when compared to those
who have never used cannabis.
Biological plausibility of cannabis in testicular
carcinogenesis
The primary psychoactive component of the cannabis
plant – delta-9-tetrahydrocannabinol, or THC – stimu-
lates neural cannabinoid receptors, mimicking the action
of endogenous cannabanoids (termed endocannabanoids).
Fig. 2 Forest plots – with odds ratios and heterogeneity statistics – for a ever-use, b current use, c > = weekly use, and d > =10 years of use.
(Total = all histological types)
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The position of these cannabinoid receptors in the basal
ganglia, hippocampus, cerebellum and neocortex explains
the common neurophysiological effects of cannabis inges-
tion; however, these receptors are also expressed in per-
ipheral locations, including the testis [22].
The biological plausibility of the link between cannabis
exposure and testicular cancer is thought to be related
to disruptions to the hypothalamic–pituitary–testicular
axis – an endocrine feedback system which, among
other actions, assists with spermatogenesis [23]. It is
thought that cannabis exposure – and subsequent stimu-
lation of cannabinoid receptors – disrupts normal hor-
mone regulation and testicular function, and that this
disruption leads to carcinogenesis [23]. However, evi-
dence regarding the association between regulation of
normal testicular function and tumour development re-
mains inconclusive; and given the complex and multifa-
ceted influence of cannabinoid receptor stimulation on
biological processes [9], the path from cannabis expos-
ure to testicular carcinogenesis remains unclear.
Timing of cannabis exposure
The observation of an association between cannabis use
and non-seminoma TGCT development – but not
seminoma development – is intriguing. As discussed by
Skeldon and Goldenberg [23], this association directs
our attention to puberty (rather than later in life) as the
key point of exposure. Non-seminoma tumours are typ-
ically diagnosed seven [11] to ten [12] years earlier than
seminoma tumours. Interestingly, one study included in
the current review that asked cases and controls about
the timing of their first cannabis use showed that those
who first-used before the age of 18 years were substan-
tially more likely to develop a non-seminoma TGCT
compared to never-users (adjusted OR: 2.80, 95 % CI
1.60–5.10), but that those aged 18 or older were not
(OR: 1.30, 95 % CI 0.60–3.20) [9]. This may suggest
that any carcinogenic disruption of interest to the
hypothalamic–pituitary–testicular axis occurs during
(or before) puberty [23]; however it is also possible that
early initiation of cannabis exposure is a marker of
other mediating factors, such as duration and frequency
of cannabis use later in life. Another possibility is that
since those cases that developed non-seminoma tu-
mours were younger at the time of data collection than
those who developed seminoma tumours, they may
have been more likely to either recall or report
marijuana use. Such a scenario would have the effect of
exaggerating the association between cannabis use and
non-seminoma development. However, it should be
noted that this exaggeration would only occur if the
age-matched controls who participated in these studies
were not affected by this pattern of differential report-
ing by age – in other words, if the cannabis use
reported by controls was accurate. This is an area that
warrants further exploration.
An as-yet unexplored concept regarding the timing of
cannabis exposure is the period during prenatal and
early childhood development. Best current evidence sug-
gests that TC predisposition is determined prenatally;
thus, it is possible that those who positively identify as
current, chronic cannabis users are also more likely to
have been exposed to cannabis during perinatal and/or
early childhood development. In other words, it is pos-
sible that primary cannabis use could be a proxy for
second-hand exposure to cannabis during the prenatal
and/or early childhood period. Such exposure would be
congruent with a pre-adulthood disruption to the
hypothalamic-pituitary-testicular axis, albeit via a sec-
ondary rather than primary source. However this asso-
ciation remains speculative and further research is
required regarding the role of non-primary exposure to
cannabis during the prenatal and early childhood
period as a risk factor for the development of TGCT.
Strengths and weaknesses of included studies
The three case–control studies examined for this review
had strengths in a number of areas; however, each of the
studies had acknowledged weaknesses, one of these be-
ing the ascertainment of cannabis exposure.
For all three studies, exposure to cannabis was mea-
sured using self-report – either during a face-to-face
interview [8, 9] or on a written questionnaire [7]. Accord-
ing to the Newcastle-Ottawa Scale, one of the optimum
mechanisms to measure exposure – and ostensibly min-
imise risk of information bias – is via a structured inter-
view, where the interviewer is blinded to the case/control
status of the participant. There is no record in any of the
included studies that the interviewers were blinded to the
status of the participant. The importance of this is that we
do not whether (and to what extent) the association be-
tween cannabis exposure and TC was affected by inter-
viewer bias (i.e., the interviewer knowing the case/control
status of the participant, and inadvertently leading the par-
ticipant toward certain answers). However, it would seem
unlikely that interviewer bias could explain all or even
some of the observed associations between cannabis use
and TGCT development; for example, it is difficult to im-
agine a scenario where knowledge of case/control status
would cause interviewers to inadvertently lead those with
non-seminoma tumours toward one response, and those
with seminoma tumours to another.
In the presence of an association between current can-
nabis use and testicular cancer development, it would
also be desirable to validate self-reported current (or
non-current) use via an appropriate specimen-based test.
[24] However the absence of a valid and easily-obtainable
biomarker that does not involve the participant providing
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a urine sample may render such an approach untenable. It
is possible that the use of self-report only will underesti-
mate current use of cannabis [24–26]; however there is
also some evidence that self-report is an efficacious means
of classifying current (or recent) exposure to cannabis
among men of similar age to participants of the three in-
cluded studies [27].
If the cases and controls are equally likely to either
under- or over-report cannabis exposure, then the im-
pact on the observed association between cannabis use
and TGCT development would likely be to attenuate it.
However, if TGCT cases are more likely to report/recall
cannabis use than controls – because of concern that
cannabis or similar exposures might be a cause of their
cancer, or a similar reason – then this may serve to ex-
aggerate the reported association away from the null. Of
course, it is entirely possible that the same exaggeration
could occur if cases reported their use accurately, but
controls under-reported their use.
The second major weakness for two of the three in-
cluded studies was low and differential response rates. In
one study, the response rate was substantially lower
among the controls than the cases [9]. If the reported
cannabis use was different among those controls who
responded compared with those who did not, and if the
same differential is not present for the cases who
responded and cases who did not respond, this will re-
sult in biased OR. For example, if the controls who
responded had lower rates of cannabis use than non-
responding controls, this will lead to an overestimate of
the cannabis-TGCT association. Unusually in a second
study, the control group had a substantially higher re-
sponse rate than the case group [7]. In this study, the
controls were friends of the cases, which may explain
their willingness to participate in the study. However it
is not clear why the response rate among cases was so
low. For this latter study, it may be reasonable to assume
that cannabis use might have been more similar between
cases and controls than if unrelated controls were used.
If this is true, we might expect that the ORs in this study
would be biased towards the null. Reassuringly, the re-
sults of all three studies were reasonably consistent des-
pite the different potential sources of selection bias.
Finally, when considering the role of cannabis in the
development of testicular cancer we must also consider
the likely pervasiveness of this exposure. For example, it
was estimated in the World Drug Report that 12 % of
U.S. residents aged 12 or older had used cannabis in
2012 [2], with 36 % of U.S. college students reported to
have used the drug in 2013 [28]. Given this pervasive-
ness among young adults, it is likely that ‘ever-use’ will
include many individuals with very low exposure to can-
nabis – meaning that ever-use is unlikely to be a true
measure of meaningful cannabis exposure.
It is also worth noting that of all the exposure vari-
ables included in our meta-analysis, the greatest hetero-
geneity between studies was observed for the ever-use
variable (I2 > 50 %). The source of this heterogeneity is
obscure and likely to be multifaceted – but could plaus-
ibly be due to heterogeneity between study populations
in terms of a) pervasiveness of cannabis ever-use and/or
b) willingness to report it. For example, fewer controls
in the study by Trabert et al. (55 %) [7] reported ever-
use of cannabis compared to the study by Daling et al.
(68 %) [9].
Conclusions
Using meta-analysis of published studies, we observed
that a) current, b) chronic, and c) frequent cannabis use
is associated with the development of TGCT – particu-
larly non-seminoma TGCT – at least when compared to
never-use of the drug. We found inconclusive evidence
regarding the relationship between ever- and former-use
of cannabis and TGCT development. However, it must
be noted that these observations were derived from only
three published studies; that these studies were all con-
ducted in the United States; and the majority of data col-
lection occurred during the 1990’s.
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